{
    "clinical_study": {
        "@rank": "75731", 
        "arm_group": {
            "arm_group_label": "XmAb7195 or Placbo", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, single\n      ascending dose study to investigate the safety, tolerability, and pharmacokinetics of\n      XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels."
        }, 
        "brief_title": "Safety and Tolerability of XmAb\u00ae7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Allergic Rhinitis", 
            "Allergic Conjunctivitis", 
            "Atopic Dermatitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic", 
                "Dermatitis", 
                "Dermatitis, Atopic", 
                "Rhinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult males and females 18 to 50 years of age\n\n          -  Part 1: Healthy subjects with no clinically significant abnormality identified on\n             medical or laboratory evaluation and no history of any clinically significant\n             disorder, condition, or disease that would pose a risk to subject safety or interfere\n             with the study evaluation, procedures, or completion;\n\n          -  Part 2: Otherwise healthy male and female subjects with a history of allergic\n             rhinitis and/or conjunctivitis and/or atopic dermatitis with an elevated serum IgE\n\n          -  Subjects who are able and willing to give written informed consent;\n\n          -  Subjects who have the ability to complete all study assessments;\n\n          -  Subjects who are willing to forego other forms of experimental treatment during the\n             study.\n\n        Exclusion Criteria:\n\n          -  Subjects who have a clinically relevant history or presence of respiratory,\n             gastrointestinal, renal, hepatic, hematological, lymphatic, neurological,\n             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,\n             dermatological, connective tissue diseases, or disorders (other than allergic\n             rhinitis and/or conjunctivitis and/or atopic dermatitis in Part 2) that would pose a\n             significant risk to subject safety or significantly interfere with the study\n             evaluation, procedures, or completion\n\n          -  Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus\n             (HCV) antibody and/or human immunodeficiency virus (HIV) Type I or Type II tests at\n             Screening;\n\n          -  Subjects who do not agree to use medically acceptable methods of contraception (as\n             defined in the protocol);\n\n          -  Subject is pregnant or breast feeding, or planning to become pregnant within 3 months\n             of administration of XmAb7195;\n\n          -  Subjects who have used any investigational drug in any clinical trial within 8 weeks\n             prior to admission (Day -1), or have used an experimental monoclonal antibody;\n\n          -  Subjects with prior exposure to a monoclonal antibody;\n\n          -  Subjects with a history of anaphylaxis;\n\n          -  Subjects who have received live vaccines \u2264 3 months from Screening;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148744", 
            "org_study_id": "XmAb7195-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "XmAb7195 or Placbo", 
                "description": "Single IV infusion of XmAb7195 or placebo", 
                "intervention_name": "XmAb7195", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "XmAb7195 or Placbo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "email": "Heather.Karabaich@parexel.com", 
                "last_name": "Heather Karabaich", 
                "phone": "410-350-7592"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21225"
                }, 
                "name": "Parexel Baltimore Early Phase Clinical Unit"
            }, 
            "investigator": {
                "last_name": "Ronald Goldwater, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb\u00ae7195", 
        "overall_official": {
            "affiliation": "Parexel Baltimore Early Phase Clinical Unit", 
            "last_name": "Ronald Goldwater, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number, type and severity of adverse events, vital signs, electrocardiogram (ECGs), laboratory tests, and physical examinations will be reported during the study from randomization up to Day 43", 
            "measure": "Number of adverse events including type and severity", 
            "safety_issue": "Yes", 
            "time_frame": "Date of randomization up to Day 43"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148744"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmocokinetic (PK) analysis for levels of XmAb7195 will be determined in subjects blood from time of initial dosing up to Day 43", 
                "measure": "Blood concentration of XmAb7195", 
                "safety_issue": "No", 
                "time_frame": "Time of dosing up to Day 43"
            }, 
            {
                "description": "Presence of human anti-human antibodies will be assessed from time of dosing up to Day 43", 
                "measure": "Blood levels of human anti-human antibodies", 
                "safety_issue": "No", 
                "time_frame": "Time of dosing up to Day 43"
            }
        ], 
        "source": "Xencor, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xencor, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}